AirSculpt Technologies Maps Fragile Turnaround In 2026

Airsculpt Technologies, Inc. ((AIRS)) has held its Q4 earnings call. Read on for the main highlights of the call.

AirSculpt Technologies’ latest earnings call painted a picture of a business in the midst of a fragile turnaround. Management highlighted improving margins, better same‑store sales trends, and traction in new services, yet these gains were offset by double‑digit revenue declines, weaker cash generation, and lingering balance‑sheet and operational risks that keep the recovery story far from assured.

Same‑Store Sales Turn Positive After Deep Declines

Same‑store sales trends improved sharply over the past year, reversing from roughly a 22% decline at the start of 2025 to positive territory in February 2026. Management said March continued this favorable pattern and now expects first‑quarter 2026 same‑store revenue to be roughly flat, matching the midpoint of its earlier revenue range and signaling a potential inflection.

Q4 EBITDA Rises on Margin Expansion

Fourth‑quarter adjusted EBITDA reached $2.5 million, representing 7.4% of revenue and a $0.6 million increase versus Q4 2024. The lift was driven by about two percentage points of gross margin expansion to roughly 59% and better operating leverage in SG&A, indicating that efficiency measures are starting to flow through to the bottom line.

Cost Cuts Deliver Savings Without Inflating Acquisition Costs

Management reported more than $4 million in annualized cost savings achieved in 2025 as part of a broader discipline push. SG&A fell by about $5 million in the fourth quarter compared with the prior year, while customer acquisition costs held steady at roughly $3,300 per case, suggesting the company is tightening its belt without overpaying to drive demand.

Debt Paydown Improves Leverage but Liquidity Stays Thin

The company paid down $19 million of debt in 2025, including $14 million on its term loan and $5 million on its revolver, and more than $30 million over the last five quarters. Year‑end gross debt stood at $56 million with leverage just under 3x, and after raising $14.8 million via an ATM in Q1 and paying down another $11 million, management reiterated its goal of reducing net leverage below 2.5x.

New Skin Services Tap Into GLP‑1‑Driven Demand

AirSculpt rolled out stand‑alone skin‑tightening offerings across its centers and piloted skin excision, or skin‑removal procedures, as it seeks growth beyond core body contouring. The company completed more than 100 skin‑removal surgeries in the fourth quarter of 2025 and sees a long‑term market opportunity exceeding $100 million for these services, closely tied to demand from patients using GLP‑1 weight‑loss drugs.

2025 Revenue and Q4 Sales Show Double‑Digit Declines

Despite the improving trends late in the year, Q4 revenue fell to $33.4 million, down roughly 15% from the prior‑year period, with same‑store revenue in the quarter off about 16%. For fiscal 2025, total revenue was $151.8 million, a decline of approximately 15.8% versus 2024, underscoring the depth of the downturn the company is working to reverse.

Full‑Year EBITDA and Margins Under Pressure

Full‑year 2025 adjusted EBITDA came in at about $15 million, equating to a roughly 10% adjusted EBITDA margin. That compares with approximately $21 million and a 12% margin in 2024, representing around $6 million of EBITDA erosion and a two‑percentage‑point margin contraction, even as recent quarter trends show some stabilization.

Operating Cash Flow Plunges, Tightening Financial Flexibility

Cash flow from operations dropped to $3.1 million in 2025 from $11.4 million in 2024, a decline of about $8.3 million or roughly 73%. This sharp pullback in internally generated cash adds pressure to a balance sheet that is already contending with ongoing leverage and the need to support marketing, new services, and potential refinancing.

Low Cash and Refinancing Needs Keep Risk Elevated

At year‑end, AirSculpt held $8.4 million in cash against $56 million of gross debt, leaving limited cushion despite recent deleveraging. Management is targeting net debt leverage below 2.5x and pursuing a term‑loan refinancing, but investors must weigh the company’s progress against its dependence on successful refinancing and disciplined execution to maintain liquidity.

Equipment Supply Constraints Threaten Growth in Skin Tightening

The company flagged a supply‑chain risk tied to helium plasma supplies used in its skin‑tightening procedures, noting that global disruptions could constrain access. With part of the supply base offline, these constraints could limit the pace at which AirSculpt can scale one of its key new service lines, potentially slowing revenue growth from an otherwise promising category.

Control Weaknesses Surface in Lease Accounting Review

Management disclosed that a reconciliation issue and a review of lease accounting under ASC 842 led to immaterial prior‑year adjustments, including a gross‑up of right‑of‑use assets and lease liabilities of about $3.8 million and $3.5 million. The resulting delay in filing the 10‑K underscored the need to strengthen financial reporting controls, an area likely to draw investor scrutiny until processes are visibly improved.

Guidance Signals Cautious Recovery Back‑End Loaded in 2026

For 2026, AirSculpt guided revenue to a range of $151 million to $157 million, with the midpoint implying about 3% comparable growth excluding the London location, and projected adjusted EBITDA of $15 million to $17 million. The outlook assumes flat same‑store sales in Q1 with momentum building through the year, integrates the annualized benefit of 2025 cost actions with selective reinvestment, and emphasizes a balance‑sheet focus, including no new clinic openings and continued deleveraging toward its net leverage target.

AirSculpt’s earnings call laid out a hopeful yet fragile turnaround narrative, as management works to stabilize same‑store trends and expand higher‑margin services while chipping away at debt. Investors tracking the stock will be weighing early operational gains and new‑service momentum against ongoing revenue pressure, thin liquidity, and the execution risks embedded in the company’s 2026 recovery plan.